Ann-Kristin Struckmeier1, Anne Radermacher2, Michael Fehrenz2, Tamara Bellin2, Dalia Alansary3, Philipp Wartenberg4, Ulrich Boehm4, Mathias Wagner5, Anja Scheller6, Jochen Hess7, Julius Moratin8, Christian Freudlsperger8, Jürgen Hoffmann8, Lorenz Thurner9, Klaus Roemer10, Kolja Freier2, Dominik Horn2. 1. Department of Oral and Maxillofacial Surgery, Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Saar, Germany. ann-kristin.struckmeier@uks.eu. 2. Department of Oral and Maxillofacial Surgery, Saarland University Medical Center, Kirrberger Str. 100, 66421, Homburg, Saar, Germany. 3. Institute of Biophysics, Center for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Saar, Germany. 4. Department of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Homburg, Saar, Germany. 5. Department of Pathology, Saarland University Medical Center, Homburg, Saar, Germany. 6. Department of Molecular Physiology, Center for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Saar, Germany. 7. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 8. Department of Oral and Maxillofacial Surgery, University Hospital Heidelberg, Heidelberg, Germany. 9. Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg, Saar, Germany. 10. José Carreras Center for Immuno and Gene Therapy, Saarland University, Homburg, Saar, Germany.
Abstract
PURPOSE: Strategies for Indolamine-2,3-dioxygenase 1 (IDO1) inhibition in cancer immunotherapy once produced encouraging results, but failed in clinical trials. Recent evidence indicates that immune cells in the tumour microenvironment, especially macrophages, contribute to immune dysregulation and therefore might play a critical role in drug resistance. METHODS: In this study, we investigated the significance of IDO1 expressing immune cells in primary tumours and corresponding lymph node metastases (LNMs) in oral squamous cell carcinoma (OSCC) by immunohistochemistry. The link between IDO1 and macrophages was investigated by flow cytometry in tumour tissue, healthy adjacent tissue and peripheral blood mononuclear cells (PBMCs). IDO1 activity (measured as Kynurenine/Tryptophan ratio) was assessed by ELISAs. RESULTS: High IDO1 expression in tumour-infiltrating immune cells was significantly correlated with advanced stages [Spearman's rank correlation (SRC), p = 0.027] and reduced progression-free survival (multivariate Cox regression, p = 0.034). IDO1 was significantly higher expressed in PBMCs of patients in advanced stages than in healthy controls (ANOVA, p < 0.05) and IDO1+ macrophages were more abundant in intratumoural areas than peritumoural (t test, p < 0.001). IDO1 expression in PBMCs was significantly correlated with IDO1 activity in serum (SRC, p < 0.05). IDO1 activity was significantly higher in patients with LNMs (t test, p < 0.01). CONCLUSION: All in all, IDO1 expressing immune cells, especially macrophages, are more abundant in advanced stages of OSCC and are associated with reduced progression-free survival. Further investigations are needed to explore their role in local and systemic immune response. The IDO1 activity might be a suitable biomarker of metastasis in OSCC patients.
PURPOSE: Strategies for Indolamine-2,3-dioxygenase 1 (IDO1) inhibition in cancer immunotherapy once produced encouraging results, but failed in clinical trials. Recent evidence indicates that immune cells in the tumour microenvironment, especially macrophages, contribute to immune dysregulation and therefore might play a critical role in drug resistance. METHODS: In this study, we investigated the significance of IDO1 expressing immune cells in primary tumours and corresponding lymph node metastases (LNMs) in oral squamous cell carcinoma (OSCC) by immunohistochemistry. The link between IDO1 and macrophages was investigated by flow cytometry in tumour tissue, healthy adjacent tissue and peripheral blood mononuclear cells (PBMCs). IDO1 activity (measured as Kynurenine/Tryptophan ratio) was assessed by ELISAs. RESULTS: High IDO1 expression in tumour-infiltrating immune cells was significantly correlated with advanced stages [Spearman's rank correlation (SRC), p = 0.027] and reduced progression-free survival (multivariate Cox regression, p = 0.034). IDO1 was significantly higher expressed in PBMCs of patients in advanced stages than in healthy controls (ANOVA, p < 0.05) and IDO1+ macrophages were more abundant in intratumoural areas than peritumoural (t test, p < 0.001). IDO1 expression in PBMCs was significantly correlated with IDO1 activity in serum (SRC, p < 0.05). IDO1 activity was significantly higher in patients with LNMs (t test, p < 0.01). CONCLUSION: All in all, IDO1 expressing immune cells, especially macrophages, are more abundant in advanced stages of OSCC and are associated with reduced progression-free survival. Further investigations are needed to explore their role in local and systemic immune response. The IDO1 activity might be a suitable biomarker of metastasis in OSCC patients.
Authors: Sebastian Blatt; Maximilian Krüger; Thomas Ziebart; Keyvan Sagheb; Eik Schiegnitz; Elisabeth Goetze; Bilal Al-Nawas; Andreas Max Pabst Journal: J Craniomaxillofac Surg Date: 2017-02-16 Impact factor: 2.078
Authors: I Chevolet; R Speeckaert; M Schreuer; B Neyns; O Krysko; C Bachert; B Hennart; D Allorge; N van Geel; M Van Gele; L Brochez Journal: Oncoimmunology Date: 2015-04-02 Impact factor: 8.110
Authors: L Ferdinande; C Decaestecker; L Verset; A Mathieu; X Moles Lopez; A-M Negulescu; T Van Maerken; I Salmon; C A Cuvelier; P Demetter Journal: Br J Cancer Date: 2011-11-22 Impact factor: 7.640
Authors: Oscar R Colegio; Ngoc-Quynh Chu; Alison L Szabo; Thach Chu; Anne Marie Rhebergen; Vikram Jairam; Nika Cyrus; Carolyn E Brokowski; Stephanie C Eisenbarth; Gillian M Phillips; Gary W Cline; Andrew J Phillips; Ruslan Medzhitov Journal: Nature Date: 2014-07-13 Impact factor: 69.504
Authors: Panagiota Economopoulou; Athina Kladi-Skandali; Areti Strati; George Koytsodontis; Efthymios Kirodimos; Evangelos Giotakis; Pavlos Maragoudakis; Eleni Gagari; Eirini Maratou; George Dimitriadis; Ioannis Kotsantis; Elena Vagia; Maria Anastasiou; Maria Gkotzamanidou; George Kavourakis; Evi Lianidou; Amanda Psyrri Journal: ESMO Open Date: 2020-05